Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16213757 | 0.84 | RAB9A (0.39) | MEN1ALDH1A1KMT2ARAB9AL3MBTL1 | |
| SCHEMBL13377490 | 0.81 | HPGD (0.32) | HPGD | |
| SCHEMBL12977550 | 0.79 | PTGS2 (0.36) | ALDH1A1 | |
| SCHEMBL12977543 | 0.76 | ADRA2C (0.37) | MEN1ALDH1A1KMT2AL3MBTL1HPGD | |
| SCHEMBL15501032 | 0.74 | ARG1 (0.33) | — | |
| SCHEMBL13287496 | 0.73 | TLR8 (0.37) | MEN1ALDH1A1KMT2ARAB9AL3MBTL1 | |
| SCHEMBL1046977 | 0.72 | HPGD (0.51) | MEN1ALDH1A1KMT2AL3MBTL1HPGD | |
| SCHEMBL12977563 | 0.72 | PTGS2 (0.37) | ALDH1A1 | |
| SCHEMBL11938341 | 0.71 | FPR2 (0.43) | — | |
| SCHEMBL15834887 | 0.70 | HPGD (0.37) | MEN1ALDH1A1KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100098633-A1 | SELECTIVE SEPRASE INHIBITORS | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100098633-A1 | SELECTIVE SEPRASE INHIBITORS | SLC6A7, DNPEP, PREP | MEN1 2705/4885ALDH1A1 2968/4885KMT2A 2165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.